Alembic Pharmaceuticals Limited announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection USP, 15 mg/mL, 30 mg/mL, and 60 mg/2 mL (30 mg/mL) Single Dose Vials.
This is the second injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
- Read more about Alembic receives approval from the USFDA for Ketorolac Tromethamine
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/alembic-receives-approval-from-the-usfda-for-ketorolac-tromethamine
No comments:
Post a Comment